Loading...

Derick H Lau

Title(s)Professor Emeritus, Hematology and Oncology
SchoolUniversity of California, Davis
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. PMID: 25349975.
      View in: PubMed
    2. Chen AM, Daly ME, Farwell DG, Vazquez E, Courquin J, Lau DH, Purdy JA. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy. JAMA Otolaryngol Head Neck Surg. 2014 Feb; 140(2):129-33. PMID: 24337483.
      View in: PubMed
    3. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. PMID: 24013936.
      View in: PubMed
    4. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. PMID: 24010120.
      View in: PubMed
    5. Daly ME, Lau DH, Farwell DG, Luu Q, Donald PJ, Chen AM. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer. Am J Otolaryngol. 2013 Nov-Dec; 34(6):631-5. PMID: 23954137.
      View in: PubMed
    6. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul; 14(4):351-5. PMID: 23415808.
      View in: PubMed
    7. Chen AM, Li J, Beckett LA, Zhara T, Farwell G, Lau DH, Gandour-Edwards R, Vaughan AT, Purdy JA. Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer. Laryngoscope. 2013 Jan; 123(1):152-7. PMID: 23008061.
      View in: PubMed
    8. Chen AM, Hall WH, Li J, Beckett L, Farwell DG, Lau DH, Purdy JA. Brachial plexus-associated neuropathy after high-dose radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):165-9. PMID: 22444998.
      View in: PubMed
    9. Chen AM, Farwell DG, Luu Q, Vazquez EG, Lau DH, Purdy JA. Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):170-5. PMID: 22300572.
      View in: PubMed
    10. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. PMID: 21892109.
      View in: PubMed
    11. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. PMID: 22105720.
      View in: PubMed
    12. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. PMID: 22015991.
      View in: PubMed
    13. Lau VH, Leonard RJ, Goodrich S, Luu Q, Farwell DG, Lau DH, Purdy JA, Chen AM. Voice quality after organ-preservation therapy with definitive radiotherapy for laryngeal cancer. Head Neck. 2012 Jul; 34(7):943-8. PMID: 22127963.
      View in: PubMed
    14. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177.
      View in: PubMed
    15. Chen AM, Farwell DG, Lau DH, Li BQ, Luu Q, Donald PJ. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys. 2011 Oct 01; 81(2):346-52. PMID: 20933340.
      View in: PubMed
    16. Chen AM, Chen LM, Vaughan A, Sreeraman R, Farwell DG, Luu Q, Lau DH, Stuart K, Purdy JA, Vijayakumar S. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):414-9. PMID: 20399030.
      View in: PubMed
    17. Klein EA, Guiou M, Farwell DG, Luu Q, Lau DH, Stuart K, Vaughan A, Vijayakumar S, Chen AM. Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. Int J Radiat Oncol Biol Phys. 2011 Jan 01; 79(1):60-4. PMID: 20385454.
      View in: PubMed
    18. Chen AM, Li BQ, Lau DH, Farwell DG, Luu Q, Stuart K, Newman K, Purdy JA, Vijayakumar S. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1026-32. PMID: 20231073.
      View in: PubMed
    19. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. PMID: 20148348.
      View in: PubMed
    20. Chen AM, Li BQ, Jennelle RL, Lau DH, Yang CC, Courquin J, Vijayakumar S, Purdy JA. Late esophageal toxicity after radiation therapy for head and neck cancer. Head Neck. 2010 Feb; 32(2):178-83. PMID: 19536858.
      View in: PubMed
    21. Li B, Li D, Lau DH, Farwell DG, Luu Q, Rocke DM, Newman K, Courquin J, Purdy JA, Chen AM. Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy. Radiat Oncol. 2009 Nov 12; 4:52. PMID: 19909531.
      View in: PubMed
    22. Zhu M, Baek H, Liu R, Song A, Lam K, Lau D. LAS0811: from combinatorial chemistry to activation of antioxidant response element. J Biomed Biotechnol. 2009; 2009:420194. PMID: 19794825.
      View in: PubMed
    23. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. PMID: 19494788.
      View in: PubMed
    24. Lau D, Huynh M, Johl J. A population-based clinical trial of irinotecan and Carboplatin. J Oncol. 2009; 2009:458528. PMID: 19404408.
      View in: PubMed
    25. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. PMID: 19204194.
      View in: PubMed
    26. Kim TH, Venugopal SK, Zhu M, Wang SS, Lau D, Lam KS, Clemens DL, Zern MA. A novel small molecule, LAS-0811, inhibits alcohol-induced apoptosis in VL-17A cells. Biochem Biophys Res Commun. 2009 Feb 20; 379(4):876-81. PMID: 19133235.
      View in: PubMed
    27. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. PMID: 18525299.
      View in: PubMed
    28. Calhoun R, Jablons D, Lau D, Gandara DR. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity. Oncology (Williston Park). 2008 Apr 30; 22(5):511-6; discussion 516, 521-3. PMID: 18533401.
      View in: PubMed
    29. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. PMID: 18378568.
      View in: PubMed
    30. Lee BE, Redwine J, Foster C, Abella E, Lown T, Lau D, Follette D. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. J Thorac Cardiovasc Surg. 2008 Mar; 135(3):615-9. PMID: 18329480.
      View in: PubMed
    31. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. PMID: 18166843.
      View in: PubMed
    32. Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):35-8. PMID: 18282356.
      View in: PubMed
    33. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. PMID: 18090584.
      View in: PubMed
    34. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara DR. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. PMID: 17440682.
      View in: PubMed
    35. Lee BE, von Haag D, Lown T, Lau D, Calhoun R, Follette D. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007 Mar; 133(3):746-52. PMID: 17320577.
      View in: PubMed
    36. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. PMID: 17382026.
      View in: PubMed
    37. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. PMID: 17410032.
      View in: PubMed
    38. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20; 24(33):5242-6. PMID: 17114656.
      View in: PubMed
    39. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. PMID: 17409997.
      View in: PubMed
    40. Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol. 2006 Jul; 1(6):537-44. PMID: 17409914.
      View in: PubMed
    41. Lau D, Guo L, Liu R, Marik J, Lam K. Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. Lung Cancer. 2006 Jun; 52(3):291-7. PMID: 16635537.
      View in: PubMed
    42. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006 Apr 20; 24(12):1807-13. PMID: 16622257.
      View in: PubMed
    43. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. PMID: 17409841.
      View in: PubMed
    44. Williamson SK, Crowley JJ, Lara PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. PMID: 16361616.
      View in: PubMed
    45. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. PMID: 16000614.
      View in: PubMed
    46. Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann Pharmacother. 2005 Jul-Aug; 39(7-8):1346-8. PMID: 15914516.
      View in: PubMed
    47. Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol Cancer Ther. 2005 May; 4(5):806-13. PMID: 15897245.
      View in: PubMed
    48. Chou R, Chen A, Lau D. Complete response of brain metastases to irinotecan-based chemotherapy. J Clin Neurosci. 2005 Apr; 12(3):242-5. PMID: 15851073.
      View in: PubMed
    49. Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005 Mar; 6(5):281-6. PMID: 15845178.
      View in: PubMed
    50. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. PMID: 15711184.
      View in: PubMed
    51. Mikawa M, Wang H, Guo L, Liu R, Marik J, Takada Y, Lam K, Lau D. Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells. Mol Cancer Ther. 2004 Oct; 3(10):1329-34. PMID: 15486200.
      View in: PubMed
    52. Lau D, Guo L, Gandara D, Young LJ, Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs. 2004 Oct; 15(9):871-5. PMID: 15457127.
      View in: PubMed
    53. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    54. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. PMID: 15476595.
      View in: PubMed
    55. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4205s-4209s. PMID: 15217959.
      View in: PubMed
    56. Chen AY, Chou R, Shih SJ, Lau D, Gandara D. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol. 2004 May; 50(2):111-9. PMID: 15157660.
      View in: PubMed
    57. Davies AM, Lara PN, Lau DH, Gandara DR. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. PMID: 15094177.
      View in: PubMed
    58. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. PMID: 19777702.
      View in: PubMed
    59. Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. PMID: 14967075.
      View in: PubMed
    60. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, Benfield JR. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. PMID: 14666039.
      View in: PubMed
    61. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. PMID: 14555506.
      View in: PubMed
    62. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. PMID: 12886868.
      View in: PubMed
    63. Guo LL, Guo Y, Xiao S, Lau D. Identification of lung micrometastatic tumor foci in nude mice with implanted tumor using laser capture microdissection and PCR-single-strand conformation polymorphism. Di Yi Jun Yi Da Xue Xue Bao. 2003 Jul; 23(7):725-7. PMID: 12865233.
      View in: PubMed
    64. Davies AM, Gandara DR, Lara PN, Mack PC, Lau DH, Gumerlock PH. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. PMID: 14720340.
      View in: PubMed
    65. Lau D, Guo L, Chan A, Wu R. SPR1. An early molecular marker for bronchial carcinogenesis. Methods Mol Med. 2003; 75:397-403. PMID: 12407755.
      View in: PubMed
    66. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. PMID: 12643004.
      View in: PubMed
    67. Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, Lau DH, Edelman MJ, Gandara DR. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002 Jul; 4(1):47-51. PMID: 14653876.
      View in: PubMed
    68. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. PMID: 12170446.
      View in: PubMed
    69. De Castro J, Feliu J, Casado E, Ordoñez A, González Barón M. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel. Cancer. 2002 May 15; 94(10):2797-8; author reply 2798-9. PMID: 12173351.
      View in: PubMed
    70. Lara PN, Goldberg Z, Davies A, Lau DH, Gandara DR. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. PMID: 14720347.
      View in: PubMed
    71. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. PMID: 11894020.
      View in: PubMed
    72. Cardiff RD, Bern HA, Faulkin LJ, Daniel CW, Smith GH, Young LJ, Medina D, Gardner MB, Wellings SR, Shyamala G, Guzman RC, Rajkumar L, Yang J, Thordarson G, Nandi S, MacLeod CL, Oshima RG, Man AK, Sawai ET, Gregg JP, Cheung AT, Lau DH. Contributions of mouse biology to breast cancer research. Comp Med. 2002 Feb; 52(1):12-31. PMID: 11900409.
      View in: PubMed
    73. Lara PN, Lau DH, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. PMID: 12057087.
      View in: PubMed
    74. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. PMID: 12197222.
      View in: PubMed
    75. Nguyen NT, Roberts PF, Follette DM, Lau D, Lee J, Urayama S, Wolfe BM, Goodnight JE. Evaluation of minimally invasive surgical staging for esophageal cancer. Am J Surg. 2001 Dec; 182(6):702-6. PMID: 11839342.
      View in: PubMed
    76. Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001 Dec; 34 Suppl 3:S75-80. PMID: 11740998.
      View in: PubMed
    77. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001 Jul 01; 92(1):146-52. PMID: 11443620.
      View in: PubMed
    78. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. PMID: 11488520.
      View in: PubMed
    79. Gandara DR, Lara PN, Goldberg Z, Lau DH. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Semin Oncol. 2001 Jun; 28(3 Suppl 9):26-32. PMID: 11441412.
      View in: PubMed
    80. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. PMID: 11251003.
      View in: PubMed
    81. Gandara DR, Edelman MJ, Lara PN, Lau DH. Gemcitabine in combination with new platinum compounds: an update. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 6):13-7. PMID: 11301843.
      View in: PubMed
    82. Gandara DR, Lara PN, Goldberg Z, Roberts P, Lau DH. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S5-9. PMID: 11340902.
      View in: PubMed
    83. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 2001 Jan 15; 19(2):442-7. PMID: 11208837.
      View in: PubMed
    84. Guo L, Burke P, Lo SH, Gandour-Edwards R, Lau D. Quantitative analysis of angiogenesis using confocal laser scanning microscopy. Angiogenesis. 2001; 4(3):187-91. PMID: 11911016.
      View in: PubMed
    85. Gandara DR, Edelman M, Lara P, Roberts P, Leigh B. Evolution of combined modality therapy for stage III non-small-cell lung cancer. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 5):35-41. PMID: 10981289.
      View in: PubMed
    86. Gandara DR, Lau DH, Lara PN, Edelman MJ. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):26-30. PMID: 10960942.
      View in: PubMed
    87. Lau D, Xue L, Hu R, Liaw T, Wu R, Reddy S. Expression and regulation of a molecular marker, SPR1, in multistep bronchial carcinogenesis. Am J Respir Cell Mol Biol. 2000 Jan; 22(1):92-6. PMID: 10615070.
      View in: PubMed
    88. Gandara DR, Edelman MJ, Lau D. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol. 1999 Jun; 26(3 Suppl 10):3-7. PMID: 10437743.
      View in: PubMed
    89. Lau D, Ryu J, Gandara D, Morgan R, Doroshow J, Wilder R, Leigh B. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):117-20. PMID: 10210550.
      View in: PubMed
    90. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm. 1999 Feb; 14(1):31-6. PMID: 10850285.
      View in: PubMed
    91. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DH, Schroder LE, Zangmeister MH, Balcerzak SP, Hynes HE, Gandara DR. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol. 1999; 44(6):461-8. PMID: 10550566.
      View in: PubMed
    92. Leigh BR, Lau DH. Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Am J Clin Oncol. 1998 Oct; 21(5):479-81. PMID: 9781604.
      View in: PubMed
    93. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998 Sep; 16(9):3078-81. PMID: 9738578.
      View in: PubMed
    94. Hu R, Wu R, Deng J, Lau D. A small proline-rich protein, spr1: specific marker for squamous lung carcinoma. Lung Cancer. 1998 Apr; 20(1):25-30. PMID: 9699184.
      View in: PubMed
    95. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs. 1998; 16(1):69-75. PMID: 9740546.
      View in: PubMed
    96. Lara PN, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998; 42(6):504-8. PMID: 9788578.
      View in: PubMed
    97. Lau DH, Ryu JK, Gandara DR, Morgan R, Doroshow J, Wilder R, Leigh B. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-106-S12-109. PMID: 9331132.
      View in: PubMed
    98. Lau DH, Yang B, Hu R, Benfield JR. Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis. Diagn Mol Pathol. 1997 Aug; 6(4):179-84. PMID: 9360838.
      View in: PubMed
    99. Lau DH, Ryu JK, Gandara DR. Chemoradiotherapy for poor-risk stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-110-S12-112. PMID: 9331133.
      View in: PubMed
    100. Lau DH, Ryu JK, Gandara DR, Rosenthal SA. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):157-61. PMID: 9212018.
      View in: PubMed
    101. Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol. 1997; 41(1):75-8. PMID: 9443617.
      View in: PubMed
    102. Perez EA, Coe T, Turrell C, Lau D, Campbell D, Gandara D. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J Sci Am. 1996 Sep-Oct; 2(5):286-90. PMID: 9166546.
      View in: PubMed
    103. Duran GE, Lau DH, Lewis AD, Kühl JS, Bämmler TK, Sikic BI. Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. Cancer Chemother Pharmacol. 1996; 38(3):210-6. PMID: 8646794.
      View in: PubMed
    104. Lau DH, Lu D, Hammond WG, Schmid CW, Benfield JR. Loss of nm23 and Alu DNA in human lung cancer propagated in nude mice. Cancer Lett. 1995 Nov 06; 97(2):163-8. PMID: 7497458.
      View in: PubMed
    105. Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer. 1994 Jul; 70(1):79-84. PMID: 8018545.
      View in: PubMed
    106. Lau DH, Wun T. Early manifestation of thrombotic thrombocytopenic purpura. Am J Med. 1993 Nov; 95(5):544-5. PMID: 8238072.
      View in: PubMed
    107. Lau DH, Durán GE, Sikic BI. Characterization of covalent DNA binding of morpholino and cyanomorpholino derivatives of doxorubicin. J Natl Cancer Inst. 1992 Oct 21; 84(20):1587-92. PMID: 1404452.
      View in: PubMed
    108. Lewis AD, Lau DH, Durán GE, Wolf CR, Sikic BI. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res. 1992 Aug 15; 52(16):4379-84. PMID: 1643634.
      View in: PubMed
    109. Lewis AD, Durán GE, Lau DH, Sikic BI. Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. Int J Radiat Oncol Biol Phys. 1992; 22(4):821-4. PMID: 1544857.
      View in: PubMed
    110. Lau DH, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res. 1991 Oct 01; 51(19):5181-7. PMID: 1717140.
      View in: PubMed
    111. Lau DH, Ross KL, Sikic BI. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. Cancer Res. 1990 Jul 01; 50(13):4056-60. PMID: 2162251.
      View in: PubMed
    112. Lau DH, Lewis AD, Sikic BI. Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. J Natl Cancer Inst. 1989 Jul 05; 81(13):1034-8. PMID: 2733045.
      View in: PubMed
    113. Lau DH, Henderson GL. Uptake, metabolism and efflux of l-alpha-acetylmethadol (LAAM) by rat lung tissue. J Pharmacol Exp Ther. 1978 Jul; 206(1):143-50. PMID: 660544.
      View in: PubMed
    114. Henderson GL, Wilson BK, Lau DH. Plasma l-alpha-Acetylmethadol (LAAM) after acute and chronic administration. Clin Pharmacol Ther. 1977 Jan; 21(1):16-25. PMID: 832446.
      View in: PubMed
    115. Lau DH, Henderson GL. Comparative study on the derivatization of l-alpha-acetyl-methadol metabolites for electron capture gas-liquid chromatography. J Chromatogr. 1976 Dec 22; 129:329-38. PMID: 1002792.
      View in: PubMed